The US Food and Drug Administration (FDA) conducts ongoing public health safety surveillance for drug and therapeutic biologic products. Identifying cases of acute and subacute noninfectious pneumonia supports the public health mission of the FDA.
U stekinumab (Stelara; Janssen Biotech, Inc) is a human interleukin 12 (IL-12) and IL-23 antagonist. 1 In September 2009, the US Food and Drug Administration (FDA) approved ustekinumab for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, or active psoriatic arthritis, alone or in combination with methotrexate sodium. In September 2016, the FDA approved ustekinumab for the treatment of moderately to severely active Crohn disease.
During routine surveillance, we at the FDA Division of Pharmacovigilance identified postmarketing cases of interstitial or eosinophilic pneumonia reported for ustekinumab use. The purpose of our investigation was to identify and analyze postmarketing cases of noninfectious pneumonia associated with ustekinumab use, recorded in the FDA Adverse Event Reporting System (FAERS) database or published in the medical literature. Various terminologies exist to describe and categorize lung diseases. For this investigation, we used the term noninfectious pneumonia to capture pneumonitis or pneumonia derived from a noninfectious origin (ie, drug-induced). Historically, noninfectious lung diseases have been included in the broad and heterogeneous group of disorders called interstitial lung disease (ILD). Epidemiologic studies on the occurrence of ILD in the general population have been published, but the global incidence remains unclear. A populationbased study in New Mexico by Coultas et al 2, 3 reported an incidence of ILD of 32 per 100 000 per year in males and 26 per 100 000 per year in females. Drug-induced lung disease (DILD) is often underdiagnosed and accounts for 2.5% to 3% of all ILD in some registries. 3 Diagnosis of DILD is a challenge for clinicians as it relies on excluding alternative origin of the disease. No specific finding in imaging or pathologic examination of tissue biopsy exists that can confirm the diagnosis. At best, a lung biopsy can exclude other causes.
Methods
We reviewed FAERS and PubMed from approval of the drug on September 25, 2009, through November 20, 2017, for postmarketing cases of acute and subacute noninfectious pneumonia associated with the use of ustekinumab. The FAERS database, which contains spontaneous adverse event reports submitted to the FDA, 4 supports the FDA's ongoing public health safety surveillance for drug and therapeutic biologic products. As this research was conducted under specific federal statutory authority pursuant to public health, no approval from institutional review boards or informed consent was required. 5 We included cases that reported pulmonary symptoms (eg, cough, dyspnea) and a clinical diagnosis consistent with interstitial pneumonia, eosinophilic pneumonia, pneumonitis, bronchiolitis, or other related terms to describe pulmonary inflammation of a noninfectious origin, after the use of ustekinumab (regardless of the reported indication of the drug). We excluded a case if the time to symptom onset was more than 2 years from ustekinumab initiation. We also excluded a case if an alternative origin for the noninfectious pneumonia was reported, such as history of connective tissue disease, known occupational exposure to lung irritants, or history of or preexisting lung disease.
Results
We identified 12 postmarketing cases, including 8 from the FAERS database and 4 cases from PubMed. [6] [7] [8] [9] The 12 cases comprised 7
interstitial pneumonia (58%), 3 eosinophilic pneumonia (25%), 1 organizing pneumonia (8%), and 1 hypersensitivity pneumonitis (8%) diagnoses. Of the 12 cases, 7 (58%) were men and 5 (42%) were women, with a median (range) age of 63 (27-80) years. The descriptive characteristics of the cases are presented in Table 1 .
The most commonly reported symptoms include cough, dyspnea, and fatigue. No fatalities occurred, but all cases resulted in hospitalization or required medical intervention. In 7 cases (58%), the pulmonary events led to hospitalizations, including 1 patient who developed respiratory failure that required mechanical ventilation.
Further workup in the 9 cases (75%) of interstitial pneumonia, organizing pneumonia, or hypersensitivity pneumonitis involved 1 or more of the following: chest x-ray, computed tomography, bronchoalveolar lavage, or lung biopsy. The diagnosis of the 3 cases of eosinophilic pneumonia was based on bronchoalveolar lavage findings.
Although 4 cases (33%) reported a history of using medication labeled for pneumonitis or ILD (methotrexate, infliximab, adalimumab), including 1 patient who was concurrently receiving methotrexate at the time of diagnosis, all 4 patients did not have pulmonary symptoms prior to the start of ustekinumab treatment. Two additional cases (17%) reported other possible risk factors for pneumonitis (1 patient had positive IgM antibodies to mycoplasma at a titer of 1:320 without positive cultures, and a second patient worked as a carpenter and did not routinely wear a mask), but the role of ustekinumab could not be excluded.
All 12 cases were supportive of a temporal association; in 9 cases (75%), the pulmonary symptoms appeared after 1 to 3 doses of ustekinumab. Table 2 highlights the number of ustekinumab doses administered and the time to event onset from ustekinumab initiation. Ustekinumab treatment was discontinued in all patients. Positive dechallenge, in which the patients experienced an improvement after discontinuation of ustekinumab, was reported in 7 cases (58%). In addition, 1 of these 7 cases reported
Key Points
Question Are postmarketing reports of new-onset noninfectious pneumonia associated with ustekinumab use?
Findings In this analysis of case reports, 12 cases of acute and subacute noninfectious pneumonia associated with ustekinumab use were identified. Noninfectious pneumonia included diagnoses of interstitial pneumonia, eosinophilic pneumonia, organizing pneumonia, and hypersensitivity pneumonitis.
Meaning Ustekinumab use appears to be associated with the development of clinically serious noninfectious pneumonia, a finding that has led to the addition of a new warning against this risk for users of this drug. a positive rechallenge, in which the patient's interstitial pneumonia recurred after the reintroduction of ustekinumab.
Discussion
Because the time to onset for DILD can be unpredictable, varying from days to years, 3 recognizing DILD through FAERS reports is challenging. Spontaneous reporting systems favor the identification of acute events in contrast to events that develop with chronic exposures. Because of the strengths of spontaneous reporting to identify events in close temporal association with drug initiation and because of the limitations of spontaneous reporting for latent events, we restricted our investigation to acute and subacute pulmonary events consistent with noninfectious pneumonia. The mechanism of DILD is not fully known. Many of these cases likely represent a manifestation of hypersensitivity. As described by Schwaiblmair Early recognition and appropriate management of an acute drug-induced noninfectious pneumonia may prevent progression to respiratory failure or other serious outcomes. Especially in this patient population, in which patients are immunosuppressed, the nonspecific symptoms of cough and dyspnea could be mistaken for the more commonly known risks of infection (pneumonia) or tuberculosis, as described in the ustekinumab prescribing information. 1 If a patient receiving ustekinumab presents with persistent cough or dyspnea, noninfectious pneumonia secondary to the use of ustekinumab should be considered. Although no death outcome from ustekinumab use was reported during the study period, noninfectious pneumonia can lead to death. In June 2018, the Warnings and Precautions section of the ustekinumab prescribing information was updated to include the risk of developing noninfectious pneumonia. 1 
Limitations
This study has some limitations, one of which is its retrospective design. The FAERS database is a passive surveillance system and is subject to substantial underreporting. Many factors play a role in whether an event will be reported, such as the time a product has been marketed and the severity of the event. Therefore, FAERS data cannot be used to calculate the incidence rate of an adverse event. In addition, quality can vary between reports. Despite these limitations, spontaneous reports represent a valuable tool for FDA to monitor regulated products for potential new safety signals for the general public. 
